Pleural and Pericardial Effusion After Chemoradiation Therapy in Esophageal Cancer Patients: A Predictive Model Using Mean Pericardial Irradiated Dose

Author(s):  
J. Fukada ◽  
T. Abe ◽  
A. Kumabe ◽  
H. Takaishi ◽  
Y. Kitagawa ◽  
...  
2013 ◽  
Vol 87 (3) ◽  
pp. 487-493 ◽  
Author(s):  
Junichi Fukada ◽  
Naoyuki Shigematsu ◽  
Hiroya Takeuchi ◽  
Toshio Ohashi ◽  
Yoshiro Saikawa ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Chia-Ying Li ◽  
Pei-Ming Huang ◽  
Pei-Yi Chu ◽  
Po-Ming Chen ◽  
Mong-Wei Lin ◽  
...  

Tumor recurrence is an important problem threatening esophageal cancer patients after surgery, even when they achieve a pathologic major response (pMR) after neoadjuvant concurrent chemoradiation therapy (CCRT). The predictors related to overall survival and disease progression for these patients remain elusive. We aimed to identify factors that predict disease progression and overall survival in esophageal squamous cell carcinoma (SCC) patients who achieve a pMR after neoadjuvant CCRT followed by surgery. We conducted a retrospective study to analyze the factors influencing survival and disease progression after esophagectomy for esophageal cancer patients who had a major response to CCRT, which is defined by complete pathological response or microscopic residual disease without lymph node metastasis. From our study cohort, 285 patients underwent CCRT and subsequent esophagectomy; 171 (60%) of these patients achieved pMR. After excluding patients with lymph node metastases, incomplete clinical data, and adenocarcinomas, we enrolled 117 patients in this study. We found that the CCRT regimen was the only factor that influenced overall survival. The overall survival of the patients receiving taxane-incorporated CCRT was superior to that of patients receiving traditional cisplatin and 5-fluorouracil (PF) (P=0.011). The CCRT regimen can significantly influence the clinical outcome of esophageal SCC patients who achieve pMR after neoadjuvant CCRT and esophagectomy. Incorporation of taxanes into cisplatin-based CCRT may be associated with prolonged survival.


2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Chanon Puttanawarut ◽  
Nat Sirirutbunkajorn ◽  
Suphalak Khachonkham ◽  
Poompis Pattaranutaporn ◽  
Yodchanan Wongsawat

Abstract Objective The purpose of this study was to develop a model using dose volume histogram (DVH) and dosiomic features to predict the risk of radiation pneumonitis (RP) in the treatment of esophageal cancer with radiation therapy and to compare the performance of DVH and dosiomic features after adjustment for the effect of fractionation by correcting the dose to the equivalent dose in 2 Gy (EQD2). Materials and methods DVH features and dosiomic features were extracted from the 3D dose distribution of 101 esophageal cancer patients. The features were extracted with and without correction to EQD2. A predictive model was trained to predict RP grade ≥ 1 by logistic regression with L1 norm regularization. The models were then evaluated by the areas under the receiver operating characteristic curves (AUCs). Result The AUCs of both DVH-based models with and without correction of the dose to EQD2 were 0.66 and 0.66, respectively. Both dosiomic-based models with correction of the dose to EQD2 (AUC = 0.70) and without correction of the dose to EQD2 (AUC = 0.71) showed significant improvement in performance when compared to both DVH-based models. There were no significant differences in the performance of the model by correcting the dose to EQD2. Conclusion Dosiomic features can improve the performance of the predictive model for RP compared with that obtained with the DVH-based model.


Author(s):  
J. Fukada ◽  
R. Kota ◽  
A. Kumabe ◽  
H. Takaishi ◽  
H. Takeuchi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document